Loading ARGX detail
Loading ticker data...
Loading ARGX detail
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China.
Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S. À. R. L. , Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B. V. , VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
Chart data unavailable
SG Americas Securities LLC increased its stake in argenex SE (NASDAQ: ARGX) by 94.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 3,179 shares of the company's stock after purchasing an additional 1,548 shares during the period. SG Americas Securities LLC's holdings in
Allspring Global Investments Holdings LLC trimmed its position in shares of argenex SE (NASDAQ: ARGX) by 18.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 172,732 shares of the company's stock after selling 38,598 shares during the quarter. Allspring Global Investments
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both CSL Limited Sponsored ADR (CSLLY) and argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks?
BOSTON--(BUSINESS WIRE)--eClinical Solutions LLC, a global provider of digital clinical software and services, today announced that argenx SE, a global immunology company, is expanding adoption of the elluminate Clinical Data Cloud® to improve and enhance clinical data processes. The elluminate platform is designed to improve access to and analysis of clinical trial data across sources with a central source of communication for clinical data, including Data Central for collaborative data review.
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either CSL Limited Sponsored ADR (CSLLY) or argenex SE (ARGX). But which of these two stocks is more attractive to value investors?
Alkeon Capital Management LLC grew its holdings in argenex SE (NASDAQ: ARGX) by 133.3% in the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 175,000 shares of the company's stock after acquiring an additional 100,000 shares during the quarter. Alkeon Capital
Positive results from Phase 3 ADAPT OCULUS study show VYVGART's potential as the first targeted treatment for patients living with ocular MG Additional data from ADAPT SERON – the largest study of patients with gMG who do not have detectable AChR-Ab – demonstrate VYVGART's efficacy and safety across subtypes New biomarker analysis, real-world evidence and post-hoc insights highlight VYVGART's expanding treatment approach in CIDP March 6, 2026, 7:00 AM CEST Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, will present data for VYVGART® (IV: efgartigimod alfa-fcab and SC or Hytrulo: efgartigimod alfa and hyaluronidase-qvfc) and pipeline candidates empasiprubart and adimanebart at the 2026 American Academy of Neurology (AAN) Annual Meeting in Chicago from April 18-22, 2026. “The data we will present at AAN, including new Phase 3 results in ocular myasthenia gravis, demonstrate our relentless efforts to deliver a targeted treatment option to as many patients living with MG as possible,” said Luc Truyen, M.D.
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Kamada (KMDA) and argenex SE (ARGX). But which of these two stocks presents investors with the better value opportunity right now?
argenx (NASDAQ: ARGX) used a fireside chat at the TD Cowen Health Care Conference to outline its near- and longer-term priorities, with incoming CEO Karen Massey emphasizing that the company's strategy remains centered on growth and continued innovation across its FcRn platform and an expanding pipeline beyond FcRn. Vision 2030 remains the anchor Massey said the
Eli Lilly and Company's shares rose during the quarter as Zepbound's obesity launch continued to gain strong traction. Cidara Therapeutics' shares rose further following Merck's acquisition of the company in a $9.2 billion all-cash deal announced in November 2025, representing a premium of more than 100% over the prior closing price. Doximity's stock detracted from performance as the company issued disappointing guidance for the next two quarters.
argenx (NASDAQ: ARGX) used its fourth-quarter earnings call to highlight positive Phase 3 data in ocular myasthenia gravis (MG), continued commercial momentum for VYVGART, and its first year of annual operating profitability. Phase 3 ADAPT OCULUS hit primary endpoint in ocular MG Chief Medical Officer Luc Truyen said the company's Phase 3 ADAPT OCULUS trial was
Argenx SE (NASDAQ: ARGX) on Thursday reported upbeat fourth-quarter results and announced positive topline results from the Phase 3 ADAPT OCULUS study evaluating VYVGART in adults with ocular myasthenia gravis (oMG).
For 2025, we underperformed the Benchmark, while to a lesser extent also trailing our all-cap international growth Proxy Benchmark. The underperformance was in our view attributable to an abrupt but material correction in several holdings over the potential exposure of quality growth franchises to AI disruption. Lundin Mining Corporation shares rose meaningfully during the fourth quarter after the company raised its 2025 copper production outlook and lowered its cash cost guidance.
Artisan Partners Limited Partnership trimmed its position in shares of argenex SE (NASDAQ: ARGX) by 6.9% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,186,510 shares of the company's stock after selling 163,266 shares during the quarter. argenex
argenx SE (ARGX) Q4 2025 Earnings Call Transcript
